Loading...
Market
What will be the outcome of the Stryker-Inari Medical acquisition by March 31, 2025?
3
Resolution / Starting Odds
Completed • 25%
Delayed • 25%
Cancelled • 25%
Modified Terms • 25%
Official announcements from Stryker or Inari Medical, or SEC filings
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments
Jan 6, 2025, 08:22 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 5% • 25%
More than 15% • 25%
10-15% • 25%
5-10% • 25%
Decrease • 25%
Increase by 1-5% • 25%
Increase by more than 5% • 25%
No significant change • 25%
None • 25%
3-4 • 25%
5 or more • 25%
1-2 • 25%
Other Outcome • 25%
Completed Sale • 25%
Talks Abandoned • 25%
Ongoing Negotiations • 25%
Completed • 25%
Delayed beyond 2025 • 25%
Abandoned • 25%
Other outcome • 25%
Other outcome • 25%
Acquisition completed • 25%
Offer withdrawn • 25%
Offer rejected • 25%
Valuation between $300B and $349B • 25%
Valuation at $350B or more • 25%
Deal does not finalize • 25%
Valuation between $255B and $299B • 25%
Other outcome • 25%
Both underperform market • 25%
Both outperform market • 25%
One outperforms, one underperforms • 25%
Deal modified • 25%
Deal canceled • 25%
Deal completed as planned • 25%
Deal delayed but completed • 25%